Caplight Directory>Companies>QL Biopharm-preview>Qlbiopharm


QL Biopharm

QL Biopharm

Private
BeijingHealthcare & Life Scienceshttps://qlbiopharm.com/

Last Round

Series C

Mar 2, 2026

Total Funding Raised

$144.4M

Company Overview

QL Biopharm is a biotechnology company that develops innovative drugs for chronic metabolic diseases such as obesity, diabetes, and non-alcoholic fatty liver disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

GLP-1 receptor agonistweight loss drugsobesity treatmentdiabetes treatmentultra-long-acting GLP-1peptide therapeuticsonce-monthly GLP-1metabolic disease therapeuticsSemaglutide biosimilarclinical-stage biotechrecombinant protein therapeuticsbiosimilar drugslong-acting drug formulationoral peptide deliveryNASH treatmentE. coli manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

QL Biopharm Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

QL Biopharm Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series CMar 2, 2026
Series A ExtensionFeb 17, 2025
Series B ExtensionNov 27, 2023
Series BFeb 15, 2022
Series AOct 26, 2020
View all Funding Rounds

QL Biopharm Investors

Notable investors and investment history

InvestorRounds
Lanchi VenturesSeries B Extension
BioTrack CapitalSeries A
TF CapitalSeries C
Jiyuan CapitalSeries B Extension
Tigeryeah CapitalSeries C, Series A
OrbiMedSeries C
5Y CapitalSeries C
View all Investors

QL Biopharm Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

QL Biopharm Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about QL Biopharm's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Year Founded2018
Last FundingMar 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.